Daniel Dolan Net Worth

Mr. Daniel Dolan biography

Daniel Dolan is the Chief Financial Officer at Nabriva Therapeutics Plc.

How old is Mr Dolan?

Mr Dolan is 44, he's been the Chief Financial Officer of Nabriva Therapeutics Plc since . There are 17 older and no younger executives at Nabriva Therapeutics Plc. The oldest executive at Nabriva Therapeutics Plc is George Talbot, 72, who is the Independent member of the Supervisory Board.

What's Mr Dolan's mailing address?

Daniel's mailing address filed with the SEC is 414 COMMERCE DR., SUITE 120, FORT WASHINGTON, PA, 19034.

Insiders trading at Nabriva Therapeutics Plc

Over the last 8 years, insiders at Nabriva Therapeutics Plc have traded over $3,221,169 worth of Nabriva Therapeutics Plc stock and bought 436,925 units worth $1,215,585 . The most active insiders traders include Capital Viii, Llc Vivo, Bioventures Cayman Ltd Hbm, and Charles A Jr Rowland. On average, Nabriva Therapeutics Plc executives and independent directors trade stock every 33 days with the average trade being worth of $23,562. The most recent stock trade was executed by Daniel D Burgess on 2 August 2022, trading 11,341 units of NBRV stock currently worth $2,155.

What does Nabriva Therapeutics Plc do?

nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics. our goal is to become a fully integrated biopharmaceutical company focused on the research, development and commercialization of novel anti-infective products. nabriva was incorporated as a spin-off from sandoz gmbh antibiotics research institute (abri) in vienna, austria and commenced operations in february 2006. the new organization included small molecule assets, including pleuromutilin structure activity relationships (sar) knowledge and was focused on synthesis of pleuromutilins for systemic human use. following identification of our lead compound lefamulin and based on the clinical results of lefamulin for acute skin and skin structure infections. we believed that targeted in vitro spectrum of activity for the common pathogens causing community acquired bacterial pneumonia (cabp), wo

Nabriva Therapeutics Plc executives and stock owners

Nabriva Therapeutics Plc executives and other stock owners filed with the SEC include:

• Colin Broom,
  Director
• Theodore Schroeder,
  Chief Executive Officer, Director
• Steven Gelone,
  President, Chief Operating Officer
• Francesco Lavino,
  Chief Commercial Officer
• Gary Sender,
  Chief Financial Officer
• Jennifer Schranz,
  Chief Medical Officer
• Theodore R. Schroeder,
  CEO & Director
• Dr. Steven P. Gelone Pharm. D,
  Pres, COO & Director
• Dr. Colin Broom M.D.,
  Director
• Stephen Webster,
  Independent Member of the Supervisory Board
• George Talbot,
  Independent member of the Supervisory Board
• Charles Rowland,
  Independent Member of the Supervisory Board
• Carrie Bourdow,
  Independent Member of the Supervisory Board
• Robert Crotty,
  General Counsel, Secretary
• Daniel Burgess,
  Independent Chairman of the Supervisory Board
• Werner Heilmayer,
  VP of CMC & IP
• Dr. Christine J. Guico-Pabia M.B.A., M.D., M.P.H.,
  Chief Medical Officer
• Gary L. Sender,
  Consultant
• Jodi VanDerveer,
  Sr. VP & Head of HR
• J. Christopher Naftzger BA, Esq., J.D.,
  Gen. Counsel
• Daniel Dolan,
  Chief Financial Officer
• Bioventures Cayman Ltd Hbm,
  10% owner
• Elyse G. Seltzer,
  Chief Medical Officer
• J. Christopher Naftzger,
  General Counsel and Corp Sec
• Capital Viii, Llc Vivo,
  10% owner
• Mark Corrigan,
  Director
• Christine J. Guico Pabia,
  Chief Medical Officer
• Daniel Dolan,
  Chief Financial Officer
• Lisa Dalton,
  Director